Here you can find the latest news related to our company, project and collaborators.
Dr. Simó has also recently pronounced the lecture of admission as a new member of the Royal Academy of Medicine of Catalonia
The company linked to the Vall d'Hebron Research Institute (VHIR) "D-Sight" has received a million euro investment from the venture capital fund Clave Capital to develop therapies for the treatment of diabetic retinopathy and other neurodegenerative diseases of the retina, such as glaucoma.
D-Sight represents the first case of the entrepreneur in residence model promoted by the VHIR, with a history of 15 companies set up.
The investment will allow D-Sight to move forward with the first phase of clinical validation of its drug for early-stage diabetic retinopathy and glaucoma.
The Alberto Sols award recognises his contributions to diabetes research, such as the description of the mechanisms of neurodegeneration in diabetic retinopathy and new therapeutic strategies and early neuroprotective pathways.
The recognition means the admission of the current head of the Endocrinology and Nutrition Service of the Vall d'Hebron University Hospital and of the Diabetes and Metabolism research group at VHIR as a member of the RAMC.
This is the first evidence in humans that eye drops can reach the retina and modulate the action of neurons, which will change the therapeutic strategy.